U.S. Launches Section 301 Probe into Germany

The United States has launched an investigation under Section 301 against Germany to determine whether Germany's reduction of spending on innovative medicines is harming American business interests. This comes after months of dialogue between the two countries, during which Washington urged Germany to correct its stance and agree to the drug pricing agreements made with Britain to promote investment and innovation in the pharmaceutical sector.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل